{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:11:12Z","timestamp":1779102672774,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.diabres.2023.111031","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:48:20Z","timestamp":1701190100000},"page":"111031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes"],"prefix":"10.1016","volume":"207","author":[{"given":"Daniel","family":"Scarr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-8924","authenticated-orcid":false,"given":"Erik","family":"Lovblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmohsen","family":"Bakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha J.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.S.","family":"Wolever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0046","authenticated-orcid":false,"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diabres.2023.111031_b0005","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2023.111031_b0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrendo.2016.15","article-title":"Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia","volume":"12","author":"Umpierrez","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.diabres.2023.111031_b0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S2213-8587(20)30042-5","article-title":"Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes","volume":"8","author":"Ehrmann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.diabres.2023.111031_b0020","doi-asserted-by":"crossref","first-page":"e3169","DOI":"10.1002\/dmrr.3169","article-title":"Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"35","author":"Lu","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2023.111031_b0025","doi-asserted-by":"crossref","unstructured":"Cherney DZI, Bjornstad P, Perkins BA, et al. Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clin J Am Soc Nephrol. 2021:1715-1719. vol. 11.","DOI":"10.2215\/CJN.07700621"},{"issue":"10","key":"10.1016\/j.diabres.2023.111031_b0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2023.111031_b0035","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2023.111031_b0040","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2023.111031_b0045","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111031_b0050","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33(5)","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.diabres.2023.111031_b0055","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with Sodium-Glucose Cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2023.111031_b0060","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.diabres.2023.111031_b0065","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2023.111031_b0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.diabres.2023.111031_b0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.diabres.2023.111031_b0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.diabres.2023.111031_b0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.diabres.2023.111031_b0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","article-title":"Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin","volume":"184","author":"Cohen","year":"1956","journal-title":"Am J Physiol"},{"key":"10.1016\/j.diabres.2023.111031_b0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.diabres.2023.111031_b0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00592-008-0026-y","article-title":"Comparison of capillary blood ketone measurement by electrochemical method and urinary ketone in treatment of diabetic ketosis and ketoacidosis in children","volume":"45","author":"Turan","year":"2008","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.diabres.2023.111031_b0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1464-5491.2004.01374.x","article-title":"Near patient blood ketone measurements and their utility in predicting diabetic ketoacidosis","volume":"22","author":"Harris","year":"2005","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.diabres.2023.111031_b0110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2337\/dc10-1844","article-title":"Diagnostic accuracy of point-of-care testing for diabetic ketoacidosis at emergency-department triage: {beta}-hydroxybutyrate versus the urine dipstick","volume":"34","author":"Arora","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2023.111031_b0115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc07-1683","article-title":"Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?","volume":"31","author":"Sheikh-Ali","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2023.111031_b0120","first-page":"683","article-title":"Point-of-care test identifies diabetic ketoacidosis at triage","volume":"13","author":"Naunheim","year":"2006","journal-title":"Acad Emerg Med"},{"issue":"8","key":"10.1016\/j.diabres.2023.111031_b0125","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2023.111031_b0130","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/dom.14489","article-title":"Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes","volume":"23","author":"Liu","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.111031_b0135","doi-asserted-by":"crossref","unstructured":"Kopecky C, Lytvyn Y, Domenig O, et al. Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. Diabetologia. 2019:1090-1093. vol. 6.","DOI":"10.1007\/s00125-019-4871-8"},{"issue":"11","key":"10.1016\/j.diabres.2023.111031_b0140","doi-asserted-by":"crossref","first-page":"e0141085","DOI":"10.1371\/journal.pone.0141085","article-title":"Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes","volume":"10","author":"Perkins","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.diabres.2023.111031_b0145","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.diabres.2023.111031_b0150","doi-asserted-by":"crossref","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 2014:1057-8. vol. 5.","DOI":"10.1038\/ki.2014.246"},{"key":"10.1016\/j.diabres.2023.111031_b0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2023.111031_b0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/db07-1230","article-title":"The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes","volume":"57","author":"Cherney","year":"2008","journal-title":"Diabetes"},{"issue":"2\u20133","key":"10.1016\/j.diabres.2023.111031_b0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000521940","article-title":"High-throughput metabolomics and diabetic kidney disease progression: evidence from the chronic renal insufficiency (CRIC) study","volume":"53","author":"Zhang","year":"2022","journal-title":"Am J Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2023.111031_b0170","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"Glycemic targets: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111031_b0175","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216203s000lbl.pdf. Accessed August 8, 2023."},{"issue":"5","key":"10.1016\/j.diabres.2023.111031_b0180","first-page":"1","article-title":"Youth risk behavior surveillance - United States, 2009","volume":"59","author":"Eaton","year":"2010","journal-title":"MMWR Surveill Summ"},{"issue":"10","key":"10.1016\/j.diabres.2023.111031_b0185","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.2337\/diacare.17.10.1178","article-title":"Insulin omission in women with IDDM","volume":"17","author":"Polonsky","year":"1994","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2023.111031_b0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","author":"Laffel","year":"1999","journal-title":"Diabetes Metab Res Rev Nov-Dec"},{"issue":"3","key":"10.1016\/j.diabres.2023.111031_b0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/er.2012-1055","article-title":"The role of estrogens in control of energy balance and glucose homeostasis","volume":"34","author":"Mauvais-Jarvis","year":"2013","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.diabres.2023.111031_b0200","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723007945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723007945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T17:02:31Z","timestamp":1740243751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723007945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"alternative-id":["S0168822723007945"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111031","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111031"}}